Table 2.
Proportions of EPA, DPA and DHA in plasma stratified by ELOVL2 SNP genotype at baseline
| rs3734398 | rs2236212 | rs953413 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| TT n = 90 |
TC + CC n = 192 |
P* | GG n = 91 |
GC + CC n = 191 |
P* | GG n = 80 |
GA + AA n = 208 |
P* | |
| EPA | 1.15 (1.03,1.26) | 1.10 (1.02,1.19) | 0.528 | 1.15 (1.04,1.26) | 1.11 (1.02,1.19) | 0.533 | 1.16 (1.03,1.28) | 1.10 (1.02,1.18) | 0.559 |
| DPA | 0.65 (0.62,0.67) | 0.65 (0.63,0.66) | 0.950 | 0.65 (0.62,0.67) | 0.65 (0.63,0.66) | 0.877 | 0.64 (0.62,0.67) | 0.65 (0.63,0.66) | 0.620 |
| DHA | 2.53 (2.39,2.68) | 2.37 (2.27,2.46) | 0.021 | 2.53 (2.39,2.68) | 2.37 (2.27,2.47) | 0.023 | 2.54 (2.39,2.69) | 2.37 (2.28,2.47) | 0.030 |
Data are presented for subjects for whom DNA samples and plasma fatty acid measurements were available (n = 310). Data show mean (95 % CI) for each LC-PUFA as a percentage of total fatty acids measured at baseline after 4-week run-in on background diet with placebo supplement
EPA eicosapentaenoic acid; DPA docosapentaenoic acid; DHA docosahexaenoic acid
* Significance of genotype association with proportions of fatty acids with respect to SNP genotype based on a dominant model was tested by multivariate ANOVA. P-values were adjusted for BMI, age, gender and ethnicity